Last update 01 Nov 2024

Alopecia Universalis

Last update 01 Nov 2024

Basic Info

Synonyms

ALOPECIA UNIVERSALIS, ALOPECIA UNIVERSALIS CONGENITA, ALUNC

+ [19]

Introduction

A disorder of most severe form of alopecia areata, an inflammatory disease of the hair follicle, which is characterized by a complete loss of hair of the scalp and all the hair-bearing areas of the body.

Drugs associated with Alopecia Universalis

BNZ-1

Target

IL-15 x IL-2 x IL-9

Mechanism

IL-15 inhibitors [+2]

Active Org.

Equillium, Inc. [+1]

Originator Org.

Bioniz Therapeutics, Inc.

Active Indication

Alopecia Areata [+3]

Inactive Indication

Adult T-Cell Leukemia-Lymphoma [+6]

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

TIME SO-MSC-EXO (ANEXT)

Target-

Mechanism-

Active Org.

ANEXT (Shanghai) Biotechnology Co., Ltd.

Originator Org.

ANEXT (Shanghai) Biotechnology Co., Ltd.

Active Indication

Alopecia Universalis [+1]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

ATI-502

Target

JAK1 x JAK3

Mechanism

JAK1 inhibitors [+1]

Active Org.-

Originator Org.

Rigel Pharmaceuticals, Inc.

Active Indication-

Inactive Indication

Alopecia Areata [+5]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Alopecia Universalis

NCT06283316 / RecruitingNot ApplicableIIT

Systemic Treatments for Alopecia Areata Registry

A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.

Start Date17 Jan 2024

Sponsor / Collaborator-

NCT06278402 / CompletedPhase 3IIT

Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan. Efficacy of treatment in patients presenting with alopecia areata will be assessed using SALT Score on follow up at 6,12 and 24 weeks where four categories of treatment response were defined: 0 (re-growth ≤10%), 1 (11-25%), 2 (26-50%), 3 (51-75%) and 4 (re-growth >75%). Efficacy will be considered if re-growth ≥ 2.

Start Date01 Jul 2023

Sponsor / Collaborator

Jinnah Hospital Lahore

NCT05589610 / CompletedPhase 2

An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata

The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous (IV) push weekly.

Start Date19 Dec 2022

Sponsor / Collaborator

Equillium, Inc.

[+1]

100 Clinical Results associated with Alopecia Universalis

100 Translational Medicine associated with Alopecia Universalis

0 Patents (Medical) associated with Alopecia Universalis

1,048

Literatures (Medical) associated with Alopecia Universalis

01 Nov 2024·Journal of the European Academy of Dermatology and Venereology

Treatment of acute urticaria: A systematic review

Review

Author: Grosber, Martine ; Gutermuth, Jan ; Ring, Johannes ; Kortekaas Krohn, Inge ; Badloe, Fariza M. S.

AbstractThere are only a few clinical trials which address the treatment of acute urticaria (AU). Especially, the added value of systemic corticosteroids to antihistamines is unclear in treatment of severe AU. To review the existing evidence‐based approaches for AU treatment. A systematic electronic search was done in PubMed and Web of Science to retrieve all studies on the treatment of patients with AU. A descriptive synthesis was conducted based on the PRISMA statement. Quality assessment was independently performed by both reviewers (‘Cochrane risk‐of‐bias tool’ for RCTs). Ten randomized controlled trials (RCTs) (n = 857 participants) were included. Four studies assessed corticosteroid effectiveness added to antihistamines and six studies compared the efficacy of H1 and/ or H2‐antihistamines. The addition of corticosteroid (prednisone) to an antihistamine (levo)cetirizine did not improve symptoms of AU compared to antihistamine alone in two out of three RCTs. The combination of diphenhydramine (50 mg, IV) and ranitidine (50 mg, IV) or cimetidine (300 mg, IV) was most efficient for relief of urticaria in two out of five studies. Most frequent adverse effects were sedation and drowsiness. Recent guidelines on urticaria treatment mainly focus on chronic urticaria rather than on AU. Moreover, only few, small RCTs provide evidence for the management of AU. Thus, the state‐of‐the‐art management of this frequent condition remains unclear. The addition of corticosteroids to an antihistamine as treatment for AU needs to be further investigated. Well‐designed, high‐quality interventional trials are needed to establish evidence‐based treatment guidelines for AU.

01 Nov 2024·International Journal of Dermatology

Diphenylcyclopropenone alleviates trachyonychia in alopecia universalis

Letter

Author: Yorulmaz, Ahu

Trachyonychia is a nail disorder affecting the nail matrix.It generally manifests with rough, longitudinally ridged nails called opaque trachyonychia.Shiny trachyonychia, which is less commonly observed, presents shiny nails with numerous superficial pits.Trachyonychia has been associated with several diseases, most commonly alopecia areata (AA).The association between trachyonychia and AA is well-established, and some authors consider idiopathic trachyonychia a variety of AA that is limited to the nails.Moreover, an association between trachyonychia progression and AA has been described.Described here is the first reported case of trachyonychia in a patient who manifested a response to contact immunotherapy (CI) for the treatment of alopecia universalis (AU).A 12-yr-old boy presented with a 5-yr history of diffuse hair loss and a 2-yr history of rough nails.Absence of hair all over the body and trachyonychia were observedCI with diphenylcyclopropenone (DPCP) with the standard regimen was commenced.The patient was initially treated with 0.001% solution, and the concentration gradually increased.This report is the first to specify the erythematous features that cause the appearance of red lunula in trachyonychia.Moreover, changes in dermoscopic findings according to therapy have been described.Dermoscopy holds promise as a potential tool not only in the diagnosis but also in the assessment of response to therapies in trachyonychia.

20 Oct 2024·Ocular Immunology and Inflammation

CMV-Related Anterior Uveitis in a Mediterranean European Population: Clinical Features, Prognosis, and Long-Term Treatment Outcomes

Article

Author: Sidiropoulos, Georgios ; Rasoglou, Achilleas ; Tranos, Paris ; Koronis, Spyridon ; Markomichelakis, Nikos ; Stavrakas, Panagiotis ; Tranou, Marianna

PURPOSETo describe the spectrum of clinical features of cytomegalovirus-related anterior uveitis (CMV-AU) along with potential comorbidities, to calculate complication rates, and to determine risk factors and biomarkers affecting prognosis in a cohort of a Southern European Mediterranean population.MATERIALS AND METHODSIt is a retrospective, multicenter case series of consecutive patients with persisting hypertensive AU, unresponsive to topical steroids therapy, and CMV-positive essays from two uveitis referral centers were collected and analyzed.RESULTSFifty-seven eyes of 53 patients with polymerase chain reaction-verified CMV-AU over a period of 8 years were included with a mean age of 48 ± 18. Four presentation patterns were identified: 26.3% as Posner-Schlossman-like, 31.6% as chronic AU, 19.3% as presumed herpetic uveitis, 12.3% as Fuchs uveitis syndrome-like, and 10.5% without specific initial classification. About 15.8% received oral valganciclovir, 22.8% received topical valganciclovir, and 61.4% received both, for a mean duration of treatment of 44 months. AU recurrences were observed in 23 eyes with a mean of 1.5 (±1.5) recurrences per year. The only finding significantly associated with recurrence was the presence of posterior synechiae (PS) (p = 0.034). Fewer keratic precipitates (KPs) were indicative for the need of longer treatment, and endotheliitis was strongly associated with the need for filtration surgery.CONCLUSIONIn this immunocompetent southern European population, four distinct clinical presentation patterns were further confirmed, and possible biomarkers such as PS, KPs, and endotheliitis were newly reported to influence treatment outcomes. Large-scale studies could provide a more effective customized treatment protocol.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis